Using augmented reality for tracking during breast cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study explores the feasibility of using augmented reality technology to enhance preoperative tracking for patients undergoing surgery for subclinical breast cancer lesions. The approach aims to replace traditional painful and invasive methods with a non-invasive system that provides real-time 3D visualization of the breast during surgery. By fusing preoperative imaging with live video, the goal is to improve surgical precision and reduce the need for repeat surgeries due to unhealthy margins. The study will involve additional MRI imaging with gadolinium and 3D camera imaging to facilitate this innovative guidance system.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Major women
* Requiring conservative surgical management of a subclinical cancerous breast lesion (not palpable), the histology of which has been previously proven by anatomopathology;
* Having a breast MRI indication at the time of the breast assessment performed at the Centre Jean Perrin
* Ability to give informed consent to participate in the study,
* Membership of a social security scheme

Exclusion Criteria:

* Patients with breast neoplasia during pregnancy;
* Persons deprived of their liberty or under guardianship or incapable of giving consent;
* Refusal to participate.

Where it's running

• Centre Jean PERRIN
  Clermont-Ferrand, France Recruiting

Study contacts

• Study coordinator: Céleste PINARD
• Email: Celeste.PINARD@clermont.unicancer.fr
• Phone: 0473278005

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tumor and genetic features that separate platinum‑resistant ovarian cancer patients from those progression‑free at five years

  This project will test whether clinical, tissue, and genomic features can separate ovarian cancer patients who do not respond to first‑line platinum chemotherapy from those who stay progression‑free for five years.

  Recruiting Centre Jean Perrin · Clermont-Ferrand, PUY DE DOME · NCT07361471

• Circulating DNA to detect leftover disease after chemoradiotherapy for advanced head and neck cancer

  This trial will test whether a blood test for circulating tumor DNA can find leftover cancer three months after chemoradiotherapy in people with locally advanced head and neck squamous cell carcinoma enrolled in Neck-TAR.

  Recruiting at 4 sites Centre Jean Perrin · Aurillac, CANTAL and 3 other locations · NCT07178847

• Using molecular markers to predict treatment response in advanced prostate cancer

  This study is testing if certain markers in tumor DNA can help doctors predict how well a new treatment for advanced prostate cancer will work for patients.

  Recruiting Centre Jean Perrin · Clermont-Ferrand and 4 other locations · NCT06600802

• Identifying new genes linked to hereditary uveal melanoma

  This study is trying to find new genes that might make families more likely to get uveal melanoma, a type of eye cancer, to help improve care and monitoring for those affected.

  Recruiting Centre Jean Perrin · Clermont-Ferrand, Puy-de-Dôme · NCT06550674

• Detecting residual disease in advanced head and neck cancer using blood samples after radiotherapy

  This study is testing if analyzing blood samples can help find leftover cancer in patients with advanced head and neck cancer after they’ve had radiation treatment.

  Recruiting at 4 sites Centre Jean Perrin · Clermont-Ferrand, Puy-de-Dôme and 3 other locations · NCT05710679

• Developing tumor models from breast cancer samples

  This study is trying to create new tumor models from breast cancer samples to help understand how different tumors behave and respond to treatments.

  Recruiting Centre Jean Perrin · Clermont-Ferrand, Puy-de-Dôme · NCT04133077

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.